Results 61 to 70 of about 2,943 (200)
Peptidomimetic and Organometallic Derivatives of Primaquine Active against Leishmania infantum [PDF]
, 2012 The current treatment of visceral leishmaniasis is made difficult by the low efficacy, elevated costs, low bioavailability, and high toxicity of many of the available drugs.
Ana Tomas +6 more
core +1 more source
G6PD deficiency in male individuals infected by Plasmodium vivax malaria in the Brazilian Amazon: a cost study [PDF]
, 2015 BACKGROUND: Deficiency of the enzyme G6PD (G6PDd) is caused by mutations in the gene G6PD, which plays an important role in protecting the red blood cell against oxidizing agents; it is linked to chromosome X, and it may affects both sexes.
Gustavo AS Romero +5 more
core +1 more source
Tafenoquine: A Step toward Malaria Elimination.
Biochemistry, 2020 There is a pressing need for compounds with broad-spectrum activity against malaria parasites at various life cycle stages to achieve malaria elimination. However, this goal cannot be accomplished without targeting the tenacious dormant liver-stage hypnozoite that causes multiple relapses after the first episode of illness.
Kuan-Yi, Lu, Emily R, Derbyshire
openaire +4 more sources
Efficacy Evaluation of 10-Hydroxy Chondrofoline and Tafenoquine against Leishmania tropica (HTD7)
Pharmaceuticals, 2022 Leishmaniasis is affirmed as a category one disease (most emerging and unmanageable) by the World Health Organization (WHO), affecting 98 countries with an annual global incidence of ~1.2 million cases.
Sayyed Ibrahim Shah +10 more
doaj +1 more source
In vitro activity of immunosuppressive drugs against Plasmodium falciparum [PDF]
, 2014 Background Solid organ transplant recipients are particularly vulnerable for infectious diseases due to prolonged immunosuppressive treatment. Residents of endemic regions and travellers may be exposed to malaria and may, therefore, require prolonged ...
Felix Loetsch +6 more
core +2 more sources
Tropical Medicine &International Health, EarlyView.ABSTRACT Objectives This study aimed to describe the cross‐reactivity of the Abbott Bioline Malaria Ag P.f/P.f/P.v rapid diagnostic test, designed to detect Plasmodium falciparum and P. vivax, with other Plasmodium species, based on the detection of parasite lactate dehydrogenase enzymes.
Gabriel Montoia +5 more
wiley +1 more source
Biomédica: revista del Instituto Nacional de Salud, 2022 Introducción. La tafenoquina fue aprobada en el 2018 por la Food and Drug Administration de Estados Unidos y, en el 2019, por la Therapeutic Goods Administration en Australia. Su administración en dosis única y su mecanismo de acción en las fases aguda y
Astrid Lorena Cubillos +2 more
doaj +1 more source
Tafenoquine for travelers' malaria: evidence, rationale and recommendations [PDF]
Journal of Travel Medicine, 2018 Endemic malaria occurring across much of the globe threatens millions of exposed travelers. While unknown numbers of them suffer acute attacks while traveling, each year thousands return from travel and become stricken in the weeks and months following exposure.
openaire +3 more sources
Tropical Medicine &International Health, EarlyView.ABSTRACT Background Plasmodium vivax remains a challenge for malaria elimination in Nepal due to its ability to relapse. Radical cure with primaquine is effective but limited by poor adherence to the standard 14‐day low‐dose regimen. In 2022, the WHO recommended administering the same total dose (3.5 mg/kg) over 7 days to improve adherence.
Prakash Ghimire +18 more
wiley +1 more source
Differential Cytochrome P450 2D Metabolism Alters Tafenoquine Pharmacokinetics [PDF]
Antimicrobial Agents and Chemotherapy, 2015 ABSTRACTCytochrome P450 (CYP) 2D metabolism is required for the liver-stage antimalarial efficacy of the 8-aminoquinoline molecule tafenoquine in mice. This could be problematic forPlasmodium vivaxradical cure, as the human CYP 2D ortholog (2D6) is highly polymorphic.
Chau Vuong +20 more
openaire +2 more sources